A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Terminated · Phase 1, Phase 2 · NCT04799054
Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
At a glance
- Research payments reported, 2025
- $262,153
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 188
About the trial
- Sponsor
- Ascendis Pharma Oncology Division A/S
- Tested
- TransCon TLR7/8 Agonist (drug), Pembrolizumab (drug)
- Dates
- Started 2021-03-18; completion 2025-12-02
- Results posted
- Not yet
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ascendis Pharma Endocrinology Inc reported $262,153 in research payments for this study in 2025 (43 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alain Algazi, M.D. Hematology & Oncology · San Francisco, CA
- Jamie G. Rand, MD General Surgery · Duarte, CA
- Hye Sook Chon, M.D. Gynecologic Oncology · Tampa, FL
- Douglas E. Laux, MD Hematology & Oncology · Iowa City, IA
- Randy Sweis Hematology & Oncology · Chicago, IL
- Jaspreet S. Grewal, M.D., M.P.H. Hematology & Oncology · Louisville, KY
- David L. Bajor, MD Hematology & Oncology · Cleveland, OH
- Nashat Gabrail, M.D. Specialist · Canton, OH
- Diwakar Davar Hematology & Oncology · Pittsburgh, PA
- Timothy J. Panella, M.D. Medical Oncology · Knoxville, TN
- Neil D. Gross, MD ENT (Otolaryngology) · Houston, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $87,960
- Moffitt Cancer Center $48,539
- The University of Chicago International House $43,917
- University Health System, Inc, TN $37,197
- University of Pittsburgh $17,915
- University of Iowa Hospital & Clinics, IA $8,627
- Gabrail Cancer Center Research LLC $6,950
- Virginia Cancer Specialists, P.c. $6,689
- Ut MD Anderson Cancer Center $1,414
- Norton Healthcare, Inc. $1,203
- Uh Cleveland Medical Center, OH $890
- City of Hope National Medical Ctr $852
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.